Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 603 clinical trials
Dose Exploration Study OF JWCAR129 BCMA-Targeted CART for RRMM

maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple myeloma.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Muscle Stimulation for Physical Function During Stem Cell Transplant

Some blood, bone marrow, and lymphatic (hematologic) cancers such as Hodgkin/Non-Hodgkin lymphomas, chronic lymphocytic leukemia, and multiple myeloma, are over-represented in Veterans due to

  • 0 views
  • 14 May, 2022
  • 1 location
4SCAR-CD44v6 T Cell Therapy Targeting Cancer

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers. The study also aims to learn more about the function of the CD44v6 CAR-T cells and their persistency in the patients.

  • 28 views
  • 25 Jan, 2021
  • 4 locations
Daratumumab and Belatacept for Desensitization (ATTAIN)

Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors. Being "highly sensitized" means that they will likely have to wait a long time (more than 5 years) before an acceptable donor is found for …

  • 0 views
  • 24 Mar, 2022
  • 1 location
RAdiotherapy for Metastatic Spinal Cord Compression With Increased Radiation dosES (RAMSES-01)

This clinical study aims to investigate whether high-precision radiotherapy, as supposed, leads to a better control of the irradiated spinal cord metastases when compared to conventional radiotherapy. This means that a progression or recurrence of motor deficits (weakness) of the legs following radiotherapy can be avoided more effectively. Furthermore, the …

  • 0 views
  • 15 Feb, 2022
  • 1 location
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (FIL_RENOIR12)

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

neutrophil count
tumor burden
lenalidomide
rituximab
bendamustine
  • 58 views
  • 04 Oct, 2022
  • 28 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: Arm 1: Selinexor + dexamethasone + pomalidomide (SPd)

line of therapy
measurable disease
bortezomib
electrophoresis
carfilzomib
  • 57 views
  • 04 Oct, 2022
  • 16 locations
Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Trial Title: FiTNEss (UK-MRA Myeloma XIV) - Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma Overview

lenalidomide
dexamethasone
  • 0 views
  • 23 Jun, 2021
  • 109 locations
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

cohorts will start in parallel and independently. Cohort 3 will enroll approximately 30 newly diagnosed multiple myeloma (NDMM) participants with suboptimal response to ASCT.

measurable disease
induction therapy
lenalidomide
proteasome inhibitor
electrophoresis
  • 12 views
  • 10 Jul, 2022
  • 34 locations
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)

), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide

measurable disease
lenalidomide
high dose chemotherapy
velcade
bortezomib
  • 14 views
  • 04 Oct, 2022
  • 31 locations